← golden set
JNJ
JOHNSON & JOHNSONHealthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $94.2B | RevenueFromContractWithCustomerExcludingAssessedTax | Sales to customers |
| Operating income | - | not reported | not in this filing's XBRL |
| Net income attributable to the company | $26.8B | NetIncomeLoss | Net earnings from continuing operations · Net earnings |
| Diluted EPS | $11.03 | EarningsPerShareDiluted | Continuing operations - diluted · Total net earnings per share - diluted |
| Cash and cash equivalents | $19.7B | CashAndCashEquivalentsAtCarryingValue | Cash and cash equivalents (Notes 1 and 2) |
| Total assets | $199.2B | Assets | Total assets · Total liabilities and shareholders’ equity |
| Total liabilities | $117.7B | Liabilities | Total liabilities |
| Total shareholders' equity attributable to the company | - | not reported | not in this filing's XBRL |
| Net cash from operating activities | $24.5B | NetCashProvidedByUsedInOperatingActivities | Net cash flows from operating activities |
| Net cash from investing activities | -$23.6B | NetCashProvidedByUsedInInvestingActivities | Net cash (used by)/from investing activities |
| Net cash from financing activities | -$5.5B | NetCashProvidedByUsedInFinancingActivities | Net cash used by financing activities |
Income statement
table #72 · score 51 vs 28.3 runner-up · in millions| 2025 | 2024 | 2023 | |
| Sales to customers | 94,193 | 88,821 | 85,159 |
| Cost of products sold | 30,256 | 27,471 | 26,553 |
| Gross profit | 63,937 | 61,350 | 58,606 |
| Selling, marketing and administrative expenses | 23,676 | 22,869 | 21,512 |
| Research and development expense | 14,665 | 17,232 | 15,085 |
| In-process research and development impairments | 81 | 211 | 313 |
| Interest income | (1,056) | (1,332) | (1,261) |
| Interest expense, net of portion capitalized (Note 4) | 971 | 755 | 772 |
| Other (income) expense, net | (7,209) | 4,694 | 6,634 |
| Restructuring (Note 20) | 228 | 234 | 489 |
| Earnings before provision for taxes on income | 32,581 | 16,687 | 15,062 |
| Provision for taxes on income (Note 8) | 5,777 | 2,621 | 1,736 |
| Net earnings from continuing operations | 26,804 | 14,066 | 13,326 |
| Net earnings from discontinued operations, net of tax (Note 21) | - | - | 21,827 |
| Net earnings | 26,804 | 14,066 | 35,153 |
| Net earnings per share (Notes 1 and 15) | |||
| Continuing operations - basic | 11.13 | 5.84 | 5.26 |
| Discontinued operations - basic | - | - | 8.62 |
| Total net earnings per share - basic | 11.13 | 5.84 | 13.88 |
| Continuing operations - diluted | 11.03 | 5.79 | 5.20 |
| Discontinued operations - diluted | - | - | 8.52 |
| Total net earnings per share - diluted | 11.03 | 5.79 | 13.72 |
| Average shares outstanding (Notes 1 and 15) | |||
| Basic | 2,407.4 | 2,407.3 | 2,533.5 |
| Diluted | 2,429.4 | 2,429.4 | 2,560.4 |
Balance sheet
table #70 · score 53 vs 10 runner-up · in millions| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents (Notes 1 and 2) | 19,709 | 24,105 |
| Marketable securities (Notes 1 and 2) | 393 | 417 |
| Accounts receivable trade, less allowances $183 (2024, $167) | 17,178 | 14,842 |
| Inventories (Notes 1 and 3) | 14,191 | 12,444 |
| Prepaid expenses and other receivables | 4,153 | 4,085 |
| Total current assets | 55,624 | 55,893 |
| Property, plant and equipment, net (Notes 1 and 4) | 23,169 | 20,518 |
| Intangible assets, net (Notes 1 and 5) | 50,403 | 37,618 |
| Goodwill (Notes 1 and 5) | 48,772 | 44,200 |
| Deferred taxes on income (Note 8) | 6,874 | 10,461 |
| Other assets | 14,368 | 11,414 |
| Total assets | 199,210 | 180,104 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities | ||
| Loans and notes payable (Note 7) | 8,495 | 5,983 |
| Accounts payable | 11,991 | 10,311 |
| Accrued liabilities | 8,594 | 8,549 |
| Accrued rebates, returns and promotions | 19,124 | 17,580 |
| Accrued compensation and employee related obligations | 4,534 | 4,126 |
| Accrued taxes on income (Note 8) | 1,388 | 3,772 |
| Total current liabilities | 54,126 | 50,321 |
| Long-term debt (Note 7) | 39,438 | 30,651 |
| Deferred taxes on income (Note 8) | 6,791 | 2,448 |
| Employee related obligations (Notes 9 and 10) | 6,957 | 7,255 |
| Long-term taxes payable (Note 1) | 486 | 390 |
| Other liabilities | 9,868 | 17,549 |
| Total liabilities | 117,666 | 108,614 |
| Commitments and Contingencies (Note 19) | ||
| Shareholders’ equity | ||
| Preferred stock - without par value (authorized and unissued 2,000,000 shares) | - | - |
| Common stock - par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 13) | (14,930) | (11,741) |
| Retained earnings and Additional-paid-in-capital | 168,978 | 155,791 |
| Less: common stock held in treasury, at cost (Note 12) (711,904,000 shares and 712,921,000 shares) | 75,624 | 75,680 |
| Total shareholders’ equity | 81,544 | 71,490 |
| Total liabilities and shareholders’ equity | 199,210 | 180,104 |
Cash flow statement
table #78 · score 53.3 vs 10 runner-up · in millions| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net earnings | 26,804 | 14,066 | 35,153 |
| Adjustments to reconcile net earnings to cash flows from operating activities: | |||
| Depreciation and amortization of property and intangibles | 7,503 | 7,339 | 7,486 |
| Stock based compensation | 1,354 | 1,176 | 1,162 |
| Asset write-downs | 204 | 405 | 1,295 |
| Charges for acquired in-process research and development | 109 | 1,841 | 483 |
| Gain on Kenvue separation | - | - | (20,984) |
| Net gain on sale of assets/businesses | (263) | (226) | (117) |
| Deferred tax provision | 1,538 | (2,183) | (4,194) |
| Credit losses and accounts receivable allowances | (1) | 11 | - |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | |||
| Increase in accounts receivable | (1,781) | (406) | (624) |
| Increase in inventories | (1,450) | (1,128) | (1,323) |
| Increase in accounts payable and accrued liabilities | 2,377 | 1,621 | 2,346 |
| (Increase)/Decrease in other current and non-current assets | (6,167) | 1,717 | (3,480) |
| (Decrease)/Increase in other current and non-current liabilities | (5,697) | 33 | 5,588 |
| Net cash flows from operating activities | 24,530 | 24,266 | 22,791 |
| Cash flows (used by) from investing activities | |||
| Additions to property, plant and equipment | (4,832) | (4,424) | (4,543) |
| Proceeds from the disposal of assets/businesses, net | 720 | 675 | 358 |
| Acquisitions, net of cash acquired (Note 18) | (17,541) | (15,146) | - |
| Acquired in-process research and development/related milestones (Note 18) | (385) | (1,783) | (470) |
| Purchases of investments | (920) | (1,726) | (10,906) |
| Sales of investments | 1,661 | 2,462 | 19,390 |
| Credit support agreements activity, net | (2,129) | 1,517 | (2,963) |
| Other (including capitalized licenses and milestones) | (162) | (174) | 12 |
| Net cash (used by)/from investing activities | (23,588) | (18,599) | 878 |
| Cash flows (used by) from financing activities | |||
| Dividends to shareholders | (12,381) | (11,823) | (11,770) |
| Repurchase of common stock | (5,953) | (2,432) | (5,054) |
| Proceeds from short-term debt | 14,586 | 15,277 | 13,743 |
| Repayment of short-term debt | (12,330) | (9,463) | (22,973) |
| Proceeds from long-term debt, net of issuance costs | 9,138 | 6,660 | - |
| Repayment of long-term debt | (1,757) | (1,453) | (1,551) |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 3,418 | 838 | 1,094 |
| Credit support agreements activity, net | (226) | 272 | (219) |
| 2025 Annual Report | 47 | ||
| 2025 | 2024 | 2023 | |
| Settlement of convertible debt acquired from Shockwave | - | (970) | - |
| Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation | - | - | 8,047 |
| Proceeds from Kenvue initial public offering | - | - | 4,241 |
| Cash transferred to Kenvue at separation | - | - | (1,114) |
| Other | (34) | (38) | (269) |
| Net cash used by financing activities | (5,539) | (3,132) | (15,825) |
| Effect of exchange rate changes on cash and cash equivalents | 201 | (289) | (112) |
| (Decrease)/Increase in cash and cash equivalents | (4,396) | 2,246 | 7,732 |
| Cash and cash equivalents from continuing operations, beginning of period | 24,105 | 21,859 | 12,889 |
| Cash and cash equivalents from discontinued operations, beginning of period | - | - | 1,238 |
| Cash and cash equivalents, beginning of year (Note 1) | 24,105 | 21,859 | 14,127 |
| Cash and cash equivalents from continuing operations, end of period | 19,709 | 24,105 | 21,859 |
| Cash and cash equivalents from discontinued operations, end of period | - | - | - |
| Cash and cash equivalents, end of year (Note 1) | 19,709 | 24,105 | 21,859 |
| Supplemental cash flow data | |||
| Cash paid during the year for: | |||
| Interest | 1,977 | 1,990 | 1,836 |
| Interest, net of amount capitalized | 1,863 | 1,911 | 1,766 |
| Income taxes, inclusive of discontinued operations | 6,539 | 6,714 | 8,574 |
| Supplemental schedule of non-cash investing and financing activities | |||
| Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards | 2,591 | 1,551 | 1,435 |